Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Papillomavirus Infections 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Hydronephrosis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

durvalumab 1abemaciclib 1Vitamin D 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Cancer Female × durvalumab × Clear all
NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Withdrawn
BreastOther neoplasm

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡